NCT05886634View on ClinicalTrials.gov

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

May 23, 2027

Study Completion Date

May 23, 2027

Conditions
Dedifferentiated LiposarcomaSoft Tissue SarcomaSarcoma,Soft TissueSarcomaRecurrent Dedifferentiated LiposarcomaUnresectable Dedifferentiated LiposarcomaMetastatic Dedifferentiated Liposarcoma
Interventions
DRUG

Etrumadenant

Will be administered PO daily for 24 weeks

DRUG

Zimberelimab

Will be administered IV every 2 weeks for 24 weeks

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER